CliffBio
small molecule

KALETRA

LOPINAVIR; RITONAVIR

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameKALETRA
Active ingredientLOPINAVIR; RITONAVIR
Strength133.3MG;33.3MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2000
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KALETRA patent cliff — loss of exclusivity — | CliffBio